Cargando…

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Mario, Rabe, Klaus F., Corren, Jonathan, Pavord, Ian D., Katelaris, Constance H., Tohda, Yuji, Zhang, Bingzhi, Rice, Megan S., Maroni, Jaman, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H., Teper, Ariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://www.ncbi.nlm.nih.gov/pubmed/32010719
http://dx.doi.org/10.1183/23120541.00204-2019
_version_ 1783491509628174336
author Castro, Mario
Rabe, Klaus F.
Corren, Jonathan
Pavord, Ian D.
Katelaris, Constance H.
Tohda, Yuji
Zhang, Bingzhi
Rice, Megan S.
Maroni, Jaman
Rowe, Paul
Pirozzi, Gianluca
Amin, Nikhil
Ruddy, Marcella
Akinlade, Bolanle
Graham, Neil M.H.
Teper, Ariel
author_facet Castro, Mario
Rabe, Klaus F.
Corren, Jonathan
Pavord, Ian D.
Katelaris, Constance H.
Tohda, Yuji
Zhang, Bingzhi
Rice, Megan S.
Maroni, Jaman
Rowe, Paul
Pirozzi, Gianluca
Amin, Nikhil
Ruddy, Marcella
Akinlade, Bolanle
Graham, Neil M.H.
Teper, Ariel
author_sort Castro, Mario
collection PubMed
description BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 200 mg or 300 mg every 2 weeks reduced exacerbations and improved forced expiratory volume in 1 s (FEV(1)) and quality of life over 52 weeks. This analysis evaluates dupilimab's effect on lung function in the overall population, and subgroups with baseline elevated type 2 inflammatory biomarkers. METHODS: Patients were randomised to 52 weeks of subcutaneous dupilumab 200 mg every 2 weeks, 300 mg every 2 weeks, or matched-volume placebos. Lung function outcomes were analysed in the overall population, in patients with ≥150 eosinophils·µL(−1), ≥300 eosinophils·µL(−1), ≥25 ppb fractional exhaled nitric oxide (F(eNO)), and both ≥150 eosinophils·µL(−1) and ≥25 ppb F(eNO), at baseline. RESULTS: Dupilumab treatment (200 mg and 300 mg every 2 weeks) resulted in significant improvements versus placebo after 52 weeks in pre-bronchodilator FEV(1) (0.20 and 0.13 L, respectively, versus placebo) and post-bronchodilator FEV(1) (0.19 and 0.13 L, respectively), forced vital capacity (FVC) (0.20 and 0.14 L, respectively), forced expiratory flow (0.19 and 0.13 L·s(−1), respectively) and pre-bronchodilator FEV(1)/FVC ratio (1.75% and 1.61%, respectively) in the overall population (p<0.001). Difference versus placebo in post-bronchodilator FEV(1) slope of change (weeks 4–52) was significant (0.04 L·year(−1); p<0.05). Greater improvements were achieved in patients with elevated baseline blood eosinophil and/or F(eNO) levels for most outcomes. CONCLUSIONS: Dupilumab improves lung function outcomes, including large and small airway measurements and fixed airway obstruction, in patients with uncontrolled, moderate-to-severe asthma; particularly in patients with elevated biomarkers of type 2 inflammation.
format Online
Article
Text
id pubmed-6983496
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-69834962020-01-31 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Castro, Mario Rabe, Klaus F. Corren, Jonathan Pavord, Ian D. Katelaris, Constance H. Tohda, Yuji Zhang, Bingzhi Rice, Megan S. Maroni, Jaman Rowe, Paul Pirozzi, Gianluca Amin, Nikhil Ruddy, Marcella Akinlade, Bolanle Graham, Neil M.H. Teper, Ariel ERJ Open Res Original Articles BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 200 mg or 300 mg every 2 weeks reduced exacerbations and improved forced expiratory volume in 1 s (FEV(1)) and quality of life over 52 weeks. This analysis evaluates dupilimab's effect on lung function in the overall population, and subgroups with baseline elevated type 2 inflammatory biomarkers. METHODS: Patients were randomised to 52 weeks of subcutaneous dupilumab 200 mg every 2 weeks, 300 mg every 2 weeks, or matched-volume placebos. Lung function outcomes were analysed in the overall population, in patients with ≥150 eosinophils·µL(−1), ≥300 eosinophils·µL(−1), ≥25 ppb fractional exhaled nitric oxide (F(eNO)), and both ≥150 eosinophils·µL(−1) and ≥25 ppb F(eNO), at baseline. RESULTS: Dupilumab treatment (200 mg and 300 mg every 2 weeks) resulted in significant improvements versus placebo after 52 weeks in pre-bronchodilator FEV(1) (0.20 and 0.13 L, respectively, versus placebo) and post-bronchodilator FEV(1) (0.19 and 0.13 L, respectively), forced vital capacity (FVC) (0.20 and 0.14 L, respectively), forced expiratory flow (0.19 and 0.13 L·s(−1), respectively) and pre-bronchodilator FEV(1)/FVC ratio (1.75% and 1.61%, respectively) in the overall population (p<0.001). Difference versus placebo in post-bronchodilator FEV(1) slope of change (weeks 4–52) was significant (0.04 L·year(−1); p<0.05). Greater improvements were achieved in patients with elevated baseline blood eosinophil and/or F(eNO) levels for most outcomes. CONCLUSIONS: Dupilumab improves lung function outcomes, including large and small airway measurements and fixed airway obstruction, in patients with uncontrolled, moderate-to-severe asthma; particularly in patients with elevated biomarkers of type 2 inflammation. European Respiratory Society 2020-01-27 /pmc/articles/PMC6983496/ /pubmed/32010719 http://dx.doi.org/10.1183/23120541.00204-2019 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Original Articles
Castro, Mario
Rabe, Klaus F.
Corren, Jonathan
Pavord, Ian D.
Katelaris, Constance H.
Tohda, Yuji
Zhang, Bingzhi
Rice, Megan S.
Maroni, Jaman
Rowe, Paul
Pirozzi, Gianluca
Amin, Nikhil
Ruddy, Marcella
Akinlade, Bolanle
Graham, Neil M.H.
Teper, Ariel
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title_full Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title_fullStr Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title_full_unstemmed Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title_short Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
title_sort dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://www.ncbi.nlm.nih.gov/pubmed/32010719
http://dx.doi.org/10.1183/23120541.00204-2019
work_keys_str_mv AT castromario dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT rabeklausf dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT correnjonathan dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT pavordiand dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT katelarisconstanceh dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT tohdayuji dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT zhangbingzhi dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT ricemegans dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT maronijaman dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT rowepaul dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT pirozzigianluca dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT aminnikhil dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT ruddymarcella dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT akinladebolanle dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT grahamneilmh dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma
AT teperariel dupilumabimproveslungfunctioninpatientswithuncontrolledmoderatetosevereasthma